Vimarsana
Biggest News Aggregation in the World

Page 5 - Beigene News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Beigene. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Beigene Today - Breaking & Trending Today

BeiGene, Ltd. (NASDAQ:BGNE) Sees Significant Decrease in Short Interest - Vimarsana News

BeiGene, Ltd. (NASDAQ:BGNE) Sees Significant Decrease in Short Interest

BeiGene, Ltd. (NASDAQ:BGNE – Get Free Report) saw a significant decline in short interest in November. As of November 30th, there was short interest totalling 1,200,000 shares, a decline of 18.9% from the November 15th total of 1,480,000 shares. Based on an average daily volume of 213,500 shares, the short-interest ratio is presently 5.6 days. […]

ALPINE: After 39 Months, Zanubrutinib Keeps Its PFS Edge Over Ibrutinib in R/R CLL; Especially for High-Risk Patients - Vimarsana News

ALPINE: After 39 Months, Zanubrutinib Keeps Its PFS Edge Over Ibrutinib in R/R CLL; Especially for High-Risk Patients

Extended follow-up data presented at the American Society of Hematology show the advantage seen a year ago has held up for the second-generation BTK inhibitor.

Source: ajmc.com
Biden-Xi Summit Opens "Window" For Collaboration In Cancer Fight – Kevin Rudd - Vimarsana News

Biden-Xi Summit Opens "Window" For Collaboration In Cancer Fight – Kevin Rudd

China, U.S. combined account for approximately 40% of cancer deaths worldwide annually

Source: forbes.com
BeiGene, Ltd. (NASDAQ:BGNE) Short Interest Up 23.3% in November - Vimarsana News

BeiGene, Ltd. (NASDAQ:BGNE) Short Interest Up 23.3% in November

BeiGene, Ltd. (NASDAQ:BGNE – Get Free Report) saw a significant increase in short interest in the month of November. As of November 15th, there was short interest totalling 1,480,000 shares, an increase of 23.3% from the October 31st total of 1,200,000 shares. Based on an average trading volume of 213,200 shares, the short-interest ratio is […]

BeiGene Strikes Deal for Global Rights to Ensem's Phase 1-Ready Cancer Drug - Vimarsana News

BeiGene Strikes Deal for Global Rights to Ensem's Phase 1-Ready Cancer Drug

BeiGene is expanding its cancer drug pipeline, landing global rights to an Ensem Therapeutics cancer drug candidate ready to enter the clinic. The drug targets CDK2, an enzyme whose excessive activity is associated with cancer progression.